At the time of writing, Acumen Pharmaceuticals Inc [ABOS] stock is trading at $1.89, up 5.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABOS shares have gain 5.59% over the last week, with a monthly amount drifted -19.92%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Acumen Pharmaceuticals Inc [NASDAQ: ABOS] stock has seen the most recent analyst activity on July 26, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $7. Previously, Deutsche Bank started tracking the stock with Buy rating on December 12, 2023, and set its price target to $8. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $13 on May 18, 2023. BTIG Research initiated its recommendation with a Buy and recommended $15 as its price target on July 15, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on June 30, 2022, and assigned it a price target of $15. In a note dated January 21, 2022, BofA Securities upgraded an Buy rating on this stock and revised its target price from $16 to $14.
For the past year, the stock price of Acumen Pharmaceuticals Inc fluctuated between $1.72 and $5.09. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Acumen Pharmaceuticals Inc [NASDAQ: ABOS] shares were valued at $1.89 at the most recent close of the market. An investor can expect a potential return of 270.37% based on the average ABOS price forecast.
Analyzing the ABOS fundamentals
Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at -320.37%, Pretax Profit Margin comes in at -281.63%, and Net Profit Margin reading is -281.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.33 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7600 points at the first support level, and at 1.6300 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9600, and for the 2nd resistance point, it is at 2.0300.
Ratios To Look Out For
It is important to note that Acumen Pharmaceuticals Inc [NASDAQ:ABOS] has a current ratio of 10.43. Further, the Quick Ratio stands at 10.43, while the Cash Ratio is 1.67.
Transactions by insiders
Recent insider trading involved OConnell Daniel Joseph, President and CEO, that happened on Jan 19 ’24 when 15200.0 shares were sold. Chief Legal Officer & Corp Sec, Meisner Derek M completed a deal on Jan 19 ’24 to sell 8933.0 shares. Meanwhile, CFO & Chief Business Officer Zuga Matt sold 4242.0 shares on Jan 18 ’24.
